Companies › Celcuity
1 active drug program in 5 registered trials: 2 Phase 3, 2 Phase 1, 1 Phase 2; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Gedatolisib Serine/threonine-protein kinase mTOR inhibitor; PI3-kinase class I inhibitor | MTOR, PIK3R1, PIK3CB, PIK3CG, PIK3CA | Phase 3 | Breast Cancer; mCRPC (Metastatic Castration-resistant Prostate Cancer); Endometrial Cancer; TNBC - Triple-Negative Breast Cancer | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03911973 | Gedatolisib | Phase 1 | TNBC - Triple-Negative Breast Cancer | Oncology | Jul 2024 |
| NCT05501886 | Gedatolisib | Phase 3 | Breast Cancer | Oncology | Dec 2026 |
| NCT06190899 | Gedatolisib | Phase 1 | mCRPC (Metastatic Castration-resistant Prostate Cancer) | Oncology | Jan 2028 |
| NCT03675893 | Gedatolisib | Phase 2 | Endometrial Cancer | Oncology | Aug 2028 |
| NCT06757634 | Gedatolisib | Phase 3 | Breast Cancer | Oncology | Mar 2029 |
Cash and short-term investments of $643m on 2026-09-30; operating cash outflow about $237m a year; runway about 32 months at that burn, to Jun 2029; 3 of 3 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 11 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Eli Lilly Restorbio Sovargen Faeth Therapeutics iVascular S.L.U. Palvella Therapeutics Supernus Pharmaceuticals SAPU NANO (US) AstraZeneca ThromBio
BioLineRx Faeth Therapeutics SecuraBio Olema Pharmaceuticals LaNova Medicines Zhejiang
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.